Pathologist at Royal Adelaide Hospital | Professor @UniofAdelaide | Interested in breast & soft tissue pathology, breast cancer screening & digital pathology
We have uncovered a new molecular mechanism responsible for nearly one-third of sporadic schwannomas – recurrent insertion/deletion mutations in 𝑆𝑂𝑋10. https://t.co/H8SGsoOJTr
We're pleased to announce our Impact Factor for @Pathology_RCPA is 4.5, with a ranking of 18/76 among the world’s #pathology journals. Thank you and kudos to our authors, peer reviewers, editorial board and Editor-in-Chief @ProfRScolyerMIA.
Source: Clarivate 2023 #JCR2023
Hi all! Feeling great in neuro ICU at #RPAH/@SydneyLHD. Thanks so much to my friend & colleague Dr Brindha Shivalingam & team for meeting with my wife Dr Katie Nicoll & @ProfGLongMIA yesterday & for operating on me today! Thanks to friends & colleagues around world & @MelanomaAus
@ProfRScolyerMIA @SydneyLHD@ProfGLongMIA@MelanomaAus@Sydney_Uni @NSWHPathology @CPC_usyd Wishing you and Katie all the best for today's surgery Richard. Generous of you to share your progress with all of us who care for you and admire you and Katie.
https://t.co/1Na4gNm9i4
It can be done “Progress is not linear. Gender equality does not happen unless we measure it and report on it, and ensure we guard against conscious and unconscious bias. @SaraEWobker @LJTafeMD@GuptaRuta@FionaMacPath@dahlstrom_jane@priyanthi_k2017
Who dares answer these questions?
Deep soft tissue tumor of the foot in a 50+ male. Low power: partly nested to fascicular with transecting fibrous bands. High power, the cells are uniform, ovoid with pale to clear cytoplasm and prominent nucleoli.
@fouad_boulos @wusm_pathology @washupathedu Great pics, thank you. Papillary DCIS. The larger duct shows preservation of ME cells at the interface with the stroma
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial https://t.co/ZvxfWOc6oI